Impax Laboratories (NAS: IPXL) is expected to report Q2 earnings on July 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Impax Laboratories' revenues will increase 27.5% and EPS will increase 100.0%.
The average estimate for revenue is $160.5 million. On the bottom line, the average EPS estimate is $0.44.
Last quarter, Impax Laboratories chalked up revenue of $128.6 million. GAAP reported sales were 18% higher than the prior-year quarter's $108.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.52. GAAP EPS of $0.18 for Q1 were 14% lower than the prior-year quarter's $0.21 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 48.7%, 520 basis points worse than the prior-year quarter. Operating margin was 17.5%, 320 basis points worse than the prior-year quarter. Net margin was 9.6%, 320 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $626.7 million. The average EPS estimate is $1.80.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 171 members out of 183 rating the stock outperform, and 12 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is hold, with an average price target of $24.89.
Over the decades, small-cap stocks, like Impax Laboratories have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
Add Impax Laboratories to My Watchlist.
The article Can Impax Laboratories Beat These Numbers? originally appeared on Fool.com.
Seth Jaysonhad no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.